- Boston Scientific announces an exclusive agreement with Cathdata, Inc.
- Boston Scientific receives approval for a clinical trial in Germany of paclitaxel-coated stents.
- Boston Scientific acquires Embolic Protection, Inc. (EPI); Catheter Innovations, Inc.; Quanam Medical Corporation; Interventional Technologies, Inc. (IVT); Cardiac Pathways Corporation and RadioTherapeutics Corporation (RTC).
- Boston Scientific launches the Maverick® balloon dilatation catheter, which incorporates new materials and new designs of the shaft, balloon and tip to deliver excellent crossing and tracking performance.
- Boston Scientific opens a Federal Affairs Office in Washington, D.C.
- Boston Scientific announces an agreement with ESC Medical (Lumenis, Ltd.) to distribute its holmium lasers and accessories in the United States for the treatment of urological disorders.
- Boston Scientific agrees to collaborate on clinical trials with ENDOTEX Interventional Systems, Inc., in the area of carotid stenting.
- Boston Scientific announces an agreement with Natural Pharmaceuticals, Inc., under which Natural Pharmaceuticals will exclusively supply Boston Scientific with paclitaxel for use in a wide range of medical devices.
- Boston Scientific announces results in the first of a series of clinical trials designed to collect clinical information on Boston Scientific's proprietary paclitaxel-eluting stent technology for reducing coronary restenosis. Six- and nine-month follow-up results indicate zero restenosis and zero thrombosis.
- Boston Scientific announces its investment in Vitalife Life Sciences Fund, a venture capital fund located in Tel Aviv that invests in early stage private companies in the life sciences field.
- Boston Scientific expands its product offerings in the area of women's health with the acquisition of BEI Medical Systems, Inc.
- Boston Scientific acquires Smart Therapeutics, Inc., broadening its neurovascular device portfolio.
- Through an alliance with Therus Corporation, Boston Scientific obtains exclusive international distribution rights to vascular sealing devices.
- Boston Scientific forms strategic alliances with Aspect Medical Systems, Inc., Advanced Neuromodulation Systems, Inc., and TriVascular, Inc.
- Boston Scientific enters into a series of agreements with TriVascular, Inc. TriVascular was founded with the objective of improving the outcome from abdominal aortic aneurysm (AAA) therapy by developing a more durable stent graft that could be placed percutaneously (through the skin).
- Boston Scientific and Celsion Corporation announce a strategic alliance involving technology for the treatment of benign prostatic hyperplasia (BPH).
- Boston Scientific receives CE Mark for its TAXUS™ paclitaxel-eluting stent system. The Company launches the product in Europe and other international markets.
- Boston Scientific and Osiris Therapeutics, Inc., a privately held company located in Baltimore, announce a strategic alliance to develop and commercialize a new therapy to treat cardiovascular disease. The alliance will initially focus on applying mesenchymal stem cell (MSC) technology to help patients who have suffered a heart attack.
- Boston Scientific signs an agreement with MediGuide, Inc., a privately held company with development offices in Haifa, Israel, to develop and commercialize advanced imaging and navigational technologies for use in a broad range of less-invasive therapies.
- Boston Scientific and Corautus Genetics Inc. enter into a strategic alliance to develop and commercialize a gene therapy technology to treat cardiovascular disease, focusing initially on patients with severe ischemic heart disease who have been unresponsive to conventional therapies.
- Boston Scientific enters into a series of agreements with CryoVascular Systems, Inc., a privately held company located in Los Gatos, CA. CryoVascular has received U.S Food and Drug Administration clearance and the European CE Mark for a proprietary angioplasty device to treat atherosclerotic disease of the legs and other peripheral arteries.
- Boston Scientific announces that it has completed its purchase of the Addition Hill Corporate Center in Marlborough, Massachusetts. The site will initially serve as the new headquarters for the Company's Endosurgery group.
- Boston Scientific announces that it has made an equity investment in -- and secured an exclusive option to purchase -- Cameron Health, Inc. Cameron is developing a next-generation implantable cardioverter defibrillator (ICD) for the cardiac rhythm management market.
- Boston Scientific announces that it has completed a land purchase in Kerkrade, the Netherlands. The site will house the Company's new distribution center, which will serve its European, Japanese and Inter-Continental markets.
- Boston Scientific receives approval from the U.S. Food and Drug Administration to market its TAXUS® Express2™ paclitaxel-eluting coronary stent system.
- Boston Scientific receives 510(k) clearance from the U.S. Food and Drug Administration to market its Contour SE™ embolic agent for the treatment of uterine fibroids. Contour SE may be used in uterine fibroid embolization (UFE), a less-invasive alternative to surgery that generally spares the uterus in women with symptomatic uterine fibroids.
- Boston Scientific announces that it has acquired Precision Vascular Systems, Inc. Precision Vascular designs, develops and manufactures high performance medical devices for use in accessing the brain, the heart and other areas of the anatomy.
- Boston Scientific is honored with the NorthFace Scoreboard Award for Customer Service. This award is presented annually by Omega Management Group Corporation to organizations that offer exemplary customer service to their customers.
- Boston Scientific acquires Advanced Bionics, a privately held company that develops, manufactures and markets neuromodulation devices. The acquisition expanded the Company's technology portfolio into the rapidly growing implantable microelectronic device market. Advanced Bionics has developed implantable microelectronics for treating numerous neurological disorders. Its neuromodulation technology includes a range of neurostimulators (or implantable pulse generators), programmable drug pumps and cochlear implants.
- Boston Scientific celebrates its 25th anniversary. As part of the celebration, the Company announces that it plans to make a $1 million gift to Doctors Without Borders, an international medical humanitarian organization.
- Boston Scientific launches its TAXUS® Liberté™ paclitaxel-eluting coronary stent system in 18 countries. The TAXUS Liberté stent system features the Company’s next-generation Liberté™ coronary stent.
- Boston Scientific announces the implantation of its millionth TAXUS® Express2™ paclitaxel-eluting coronary stent system, marking a major milestone for the Company and for the treatment of coronary artery disease.
- Boston Scientific announces that it has acquired Advanced Stent Technologies, Inc. (AST) of Pleasanton, California. Since its founding in 1997, AST has been developing stent and stent delivery systems specifically designed to address the unique anatomical needs of coronary artery disease in bifurcated vessels.
- Boston Scientific announces that its Maple Grove, Minnesota manufacturing facility has received the 2005 Shingo Prize for Excellence in Manufacturing. The Maple Grove facility manufactures cardiovascular products, including the Company’s TAXUS® Express2™ paclitaxel-eluting coronary stent system.
- Boston Scientific announces that its Quincy, Massachusetts Customer Fulfillment Center has received the prestigious 2004 NorthFace ScoreBoardSM Award for excellence in customer service for the second consecutive year. Boston Scientific’s Quincy Customer Fulfillment Center handles approximately 70 percent of the Company’s product distribution needs. The NorthFace ScoreBoard Award, presented by the Omega Management Group Corporation, was awarded to Boston Scientific for exemplary service to its customers as well as its focus on exceeding customer expectations.
- Boston Scientific announces that it has received U.S. Food and Drug Administration (FDA) approval for its Liberté™ bare-metal coronary stent system. The Liberté stent serves as the platform for Boston Scientific’s paclitaxel-eluting stent system, TAXUS® Liberté™.
- Boston Scientific announces that the Company and its employees have donated approximately $3.3 million to the American Red Cross to help victims of hurricanes Katrina and Rita.
- Boston Scientific announces that it has received CE Mark for its TAXUS® Liberté™ paclitaxel-eluting stent system, the world’s first next-generation drug-eluting stent system.
- Boston Scientific announces that it has acquired CryoVascular Systems, Inc., a privately held company located in Los Gatos, CA. CryoVascular’s proprietary angioplasty device treats atherosclerotic disease of the legs and other peripheral arteries.
- Boston Scientific is recognized with the American Red Cross’ Circle of Humanitarian Award, the organization’s highest honor for financial support. Boston Scientific was honored for its financial support of Red Cross disaster relief efforts in the wake of Hurricanes Katrina and Rita and the tsunami that impacted Asia.
- Boston Scientific announces that it has completed its acquisition of Guidant Corporation, creating a global leader in cardiovascular devices and one of the largest medical technology companies in the world.
- Boston Scientific receives CE Mark for the PROMUS™ Everolimus-Eluting Coronary Stent System, making it the first company to offer two distinct drug-eluting stent technologies. The company launches the PROMUS Stent in 64 European and other international markets.
- Boston Scientific announces U.S. FDA approval of the PROMUS™ Everolimus-Eluting Coronary Stent System, the second member of the company’s dual-drug portfolio.
|back to top